Understand the ophthalmics partnering landscape using intelligence from 384 real-world collaboration and licensing deals.
Ophthalmics Collaboration and Licensing Deals 2019-2026 provides comprehensive intelligence on 384 partnering deals involving ophthalmic assets, technologies and development programs.
Ophthalmics partnering spans a diverse range of vision-threatening and chronic eye conditions, with transaction structures reflecting specialist technologies, targeted therapies, novel delivery approaches and distinct development pathways.
The report brings this activity together in one resource, enabling users to understand who is partnering, which ophthalmic opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in ophthalmics partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Identify comparable ophthalmics transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking ophthalmic opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable ophthalmic assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building ophthalmics portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying ophthalmics deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Ophthalmics Collaboration and Licensing Deals 2019-2026 provides comprehensive intelligence on 384 partnering deals involving ophthalmic assets, technologies and development programs.
Ophthalmics partnering spans a diverse range of vision-threatening and chronic eye conditions, with transaction structures reflecting specialist technologies, targeted therapies, novel delivery approaches and distinct development pathways.
The report brings this activity together in one resource, enabling users to understand who is partnering, which ophthalmic opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in ophthalmics partnering.
Understand the ophthalmics partnering landscape
The report analyzes ophthalmics dealmaking from 2019 to 2026, including:
- Trends in ophthalmics partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active ophthalmics dealmakers
- Leading deals by disclosed value
- How ophthalmics partnering activity is evolving
Benchmark ophthalmics deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading ophthalmics dealmakers and prospective partners
The report identifies the most active companies in ophthalmics partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking ophthalmic opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in particular technologies, delivery approaches or therapeutic targets
- Competitors pursuing related external innovation strategies
Compare partnering activity across ophthalmic indications and targets
Ophthalmics encompasses multiple therapeutic indications, biological targets and treatment approaches with differing scientific, clinical and commercial dynamics.The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how ophthalmics agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected ophthalmics transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive ophthalmics deal directory
The report includes a comprehensive directory of 384 ophthalmics collaboration and licensing deals, providing a focused resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication or target
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable ophthalmics transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking ophthalmic opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable ophthalmic assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building ophthalmics portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide ophthalmics intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying ophthalmics deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in ophthalmics dealmaking
Chapter 3 - Financial deal terms for ophthalmics partnering
Chapter 4 - Leading ophthalmics deals and dealmakers
Chapter 5 - Ophthalmics contract document directory
Chapter 6 - Ophthalmics dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio
- 4D Molecular Therapeutics
- 4P-Pharma
- A*STAR Agency for Science
- Technology and Research
- AAVnerGene
- ABB Optical Group
- Abbvie
- AbCellera Biologics
- Abeona Therapeutics
- Abpro
- ABVC BioPharma
- Accure Therapeutics
- ACE Solutech
- ActualEyes
- Acucela
- Adalvo
- Adaptive Phage Therapeutics
- Advanz Pharma
- Aequus Pharmaceuticals
- Aerie Pharmaceuticals
- AEYE Health
- AffaMed Therapeutics
- Affilogic
- AimMax Therapeutics
- AJU Pharma
- Aker BioMarine
- Alcon Laboratories
- Aldeyra Therapeutics
- Alexion Pharmaceuticals
- Alimera Sciences
- Alnylam Pharmaceuticals
- Alvotech
- Ambiopharm
- American Diabetes Association
- AmerisourceBergen
- Angios
- Apellis Pharmaceuticals
- Apexian Pharmaceuticals
- Apotex
- Applied Genetic Technologies
- Arctic Vision
- Arrotex Pharmaceuticals
- Ascidian Therapeutics
- Asimov
- Astellas Pharma
- Atsena Therapeutics
- Attillaps Holdings
- Aura Biosciences
- Aurolab
- Avanzanite Bioscience
- Avista Therapeutics
- Axantia
- AXIM Biotechnologies
- Axovia Therapeutics
- AyoxxA Biosystems
- Bascom Palmer Eye Institute
- Bausch & Lomb
- Bausch Health Companies
- Baxter International
- Bayer
- Beacon Therapeutics
- Beam Therapeutics
- Betta Pharmaceuticals
- Beyeonics Vision
- BHVI
- Bio-Techne
- BioCryst Pharmaceuticals
- Bioeq IP
- Biogen
- BioLight
- BioStem Technologies
- Blackrock Neurotech
- Blueprint Genetics
- BlueRock Therapeutics
- Boehringer Ingelheim
- Bridge Biotherapeutics
- Brigham and Women's Hospital
- BVI Medical
- C-Bridge Capital
- California Institute for Regenerative Medicine
- Capsida Biotherapeutics
- Carl Zeiss
- Carl Zeiss Meditec
- Cascade ProDrug
- Case Western Reserve University
- Catalent
- Catalyst Biosciences
- CDR-Life
- Celanese
- Cella Therapeutics
- Cell Cure Neurosciences
- Cellusion
- Celregen
- Cerevast Therapeutics
- Changchun High & New Technology Industries
- Character Biosciences
- Chiesi Farmaceutici
- Children's Hospital Los Angeles
- Children's Medical Research Institute
- China Grand Pharmaceutical
- China Medical System
- Chong Kun Dang
- Choroideremia Research Foundation
- Cipla
- City Therapeutics
- Clarion Medical Technologies
- ClearPoint Neuro
- Clearside Biomedical
- Clover Therapeutics
- Coave Therapeutics
- Coherus Biosciences
- Columbia University
- Combangio
- Copernicus Therapeutics
- Cortigent
- CORXEL Pharmaceuticals
- Covenant Surgical Partners
- Cristalia
- CROMA Pharma
- CS Pharmaceuticals
- Curacle
- CureVac
- Cyagen Biosciences
- Daiichi Sankyo
- DAVI II Farmaceutica
- De La Pena Eye Clinic
- DelSiTech
- Dermira
- Diamond Pharma Services
- Diana Davis Spencer Foundation
- Digital Diagnostics
- Diopsys
- doc.ai
- DotBio
- Dr. Agarwal’s Eye Hospitals
- Dr. Reddy's Laboratories
- Duke University
- Dyno Therapeutics
- Eastman Chemical Company
- ECM Therapeutics
- Eli Lilly
- Eluminex Biosciences
- Epimune Diagnostics
- Equinox Science
- ERS Genomics
- eSight
- Eton Pharmaceuticals
- European Organization for Research and Treatment of Cancer
- Everads Therapy
- Everest Medicines
- Eversight
- Evommune
- Evotec
- Exonate
- EyeCRO
- Eyedetec Medical
- Eyenovia
- EyePoint Pharmaceuticals
- Eyevensys
- Famy Life Sciences
- Fibrogen
- Find Therapeutics
- Florida Pharmaceutical Products
- Forge Biologics
- Formosa Pharmaceuticals
- Formycon
- ForSeeCon Eye Corporation
- Foundation Fighting Blindness
- FUJIFILM Cellular Dynamics
- Galimedix Therapeutics
- GC Biopharma
- GelMEDIX
- Gemini Therapeutics
- Genentech
- Genosity
- Gensci
- Gensight Biologics
- Gentex
- Glaucoma Research Foundation
- Glaukos
- Grifols
- Gyroscope Therapeutics
- Halozyme Therapeutics
- HanAll Biopharma
- HanchorBio
- Harrow Health
- Harvard Medical School
- HealPros
- Hemera Biosciences
- Hemostemix
- Henlius Biotech
- Hopstem Biotechnology
- Horama
- Horizon Discovery
- Horizon Europe
- Horizon Therapeutics
- Hovione
- I-MED Pharma
- IACTA Pharmaceuticals
- Ichor Life Sciences
- Ikarovec
- Immervision
- Immunocore
- ImPact Biotech
- Indoco
- Inflammasome Therapeutics
- InformedDNA
- InMed Pharmaceuticals
- Intas Pharmaceuticals
- Intellia Therapeutics
- Intratus
- Iolyx Therapeutics
- IQVIA
- IRIS
- IRIS International
- Israeli National Authority for Technological Innovation
- iSTAR Medical
- Itrom Pharmaceutical Group
- Ivantis
- iVeena Delivery Systems
- Iveric Bio
- Jaeb Center for Health Research Foundation
- Janssen Pharmaceuticals
- Janssen Research & Development
- jCyte
- Ji Xing Pharmaceuticals
- Johns Hopkins University
- Johnson & Johnson Vision
- Joslin Diabetes Center
- K2M
- Kanaph Therapeutics
- Kane Biotech
- Kemwell BioPharma
- Kiora Pharmaceuticals
- Kissei Pharmaceutical
- Klinge Biopharma
- Kodiak Sciences
- Konkuk University
- Kowa
- Kriya Therapeutics
- Kubota Vision
- Kuria Therapeutics
- Kwangdong Pharmaceutical
- Laboratoires KOL
- Laboratoires Thea
- LABORATORIOS SAVAL
- Lansheng Medical
- Lantheus Holding
- Launch Therapeutics
- Lee's Pharmaceutical
- Leiden University
- LENZ Therapeutics
- Lexitas Pharma Services
- LGC
- LianBio
- Lineage Cell Therapeutics
- LION Eye Group
- LLamasoft
- Lochan
- Locus Biosciences
- Lotus Pharmaceuticals
- Luminopia
- LumiThera
- Lunatus
- Lupin
- Maastricht University
- Magruder Eye Institute
- Mannin Research
- Marchon Eyewear
- Massachusetts Eye and Ear Infirmary
- Mawson Infrastructure
- Max-Planck
- Mayo Clinic
- McMaster University
- mCureX Therapeutics
- Medical Food Solutions Research
- Medical University of South Carolina
- Medvisis
- MeiraGTx
- MellingMedical
- Melt Pharmaceuticals
- Menicon
- Minnetronix
- miRagen Therapeutics
- MitoChem Therapeutics
- Mitsubishi Tanabe Pharma
- Mosaic Biosciences
- Mundipharma
- MyMD Pharmaceuticals
- NAMSA
- Nanomerics
- NanoPass Technologies
- Nanoscope Therapeutics
- Narayana Nethralaya Foundation
- NASA
- National Cancer Institute
- National Eye Institute
- National Institutes of Health
- National Organization for Rare Disorders
- National University of Singapore
- Neuraly
- Neurolens
- Neurophth Therapeutics
- Nevakar
- NextPharma
- NGM Biopharmaceuticals
- Nicox
- Nippon Shinyaku
- Nona Biosciences
- Northway Biotechpharma
- NovaBay Pharmaceuticals
- Novaliq
- Novartis
- Novelty Nobility
- Noveome Biotherapeutics
- Novotech
- NTC
- Numab
- NurExone Biologic
- Ocugen
- Ocular Therapeutics
- Ocular Therapeutix
- Oculis
- Oculogenex
- Ocumension Therapeutics
- Ocuphire Pharma
- Odylia Therapeutics
- OKKO Health
- OKYO Pharma
- OliX Pharmaceuticals
- Olympic Ophthalmics
- Omega Therapeutics
- Omeros
- ONL Therapeutics
- OphtAI
- Ophthotech
- Opsis Therapeutics
- Opthea
- Optifye Therapeutics
- Optina Diagnostics
- Optomed
- Opus Genetics
- Ora
- Orbis
- Orbit Biomedical
- Osmotica Pharmaceuticals
- Otsuka
- Outlook Therapeutics
- Oxford BioMedica
- Oyster Point Pharma
- Palatin Technologies
- PanOptica
- Perelman School of Medicine
- Perfuse Therapeutics
- PharmAbcine
- Pharmaleads
- Phillips-Medisize
- Pieris Pharmaceuticals
- Pierre Fabre
- Ping An Ventures
- Plex Pharmaceuticals
- Polifarma
- PolyPhotonix
- PreCerv
- Precise Biometrics
- Precision Optics
- Prevail InfoWorks
- Promedica International
- ProQR Therapeutics
- ProtoKinetix
- Provectus Biopharmaceuticals
- PTC Therapeutics
- Q BioMed
- Quest Diagnostics
- Quotient
- Rallybio
- Rayner Surgical
- Ray Therapeutics
- Re-Vana Therapeutics
- RecensMedical
- Regeneron Pharmaceuticals
- Regenerx
- Regenxbio
- RemeGen
- Remidio Innovative Solutions
- Rentschler Biotechnologie
- Resilience
- Restore Vision
- Retinagenix
- RetinAI Medical
- RetinalGeniX Technologies
- RetiSpec
- ReVision Optics
- Revision Skincare
- Revolo Biotherapeutics
- RevOpsis Therapeutics
- Ribomic
- Ripple Therapeutics
- Roche
- Rohto Pharmaceutical
- Roots Pharmaceutical
- RTW Investments
- RVL Pharmaceuticals
- RxCell
- Rxilient Biotech
- Saban Research Institute of Children's Hospital Los Angeles
- SAMIL Pharmaceuticals
- Samsara Vision
- Samsung Bioepis
- Samsung Biologics
- SanBio
- Sanofi
- Santen
- Santen Pharmaceutical
- Santhera Pharmaceuticals
- SATT Conectus Alsace
- Schepens Eye Research Institute
- Scohia Pharma
- Second Sight Medical
- Seer
- Selagine
- SemaThera
- Senju Pharmaceutical
- Senti Biosciences
- Shape Therapeutics
- SIFI (Societa Industria Farmaceutica Italiana)
- Sight Sciences
- Singapore Eye Research Institute (SERI)
- Sintetica
- SipNose
- Skye Bioscience
- Slayback Pharma
- Societal CDMO
- Sonoma Pharmaceuticals
- SparingVision
- Spark Therapeutics
- SpliceBio
- STADA Arzneimittel
- Stanford University
- Stanford University School of Medicine
- State University of New York
- StemSight
- Stuart Therapeutics
- Sun Pharma Advanced Research Company
- Sun Pharmaceutical
- Surrozen
- SwissLens
- Sydnexis
- Tabuk Pharmaceuticals
- Taiwan Liposome Company
- TALLC
- Taro Pharmaceuticals
- Tarsius Pharma
- Tarsus Pharmaceuticals
- TeamedOn International
- TearLab
- Technological University Dublin
- Tenpoint Therapeutics
- Teva Pharmaceutical Industries
- Thea Open Innovation
- ThinkCyte
- Tianjin CanSino Biotechnology
- Titan Pharmaceuticals
- Toolgen
- Topcon
- Translational Research Institute for Space Health
- Trethera
- Tufts Medical Center
- Tufts University
- Turn Biotechnologies
- UCB
- Undisclosed Company
- Uneedle
- Uni-Bio Science
- University of British Columbia
- University of California Los Angeles
- University of Colorado
- University of Florida Research Foundation
- University of Hong Kong
- University of Massachusetts Medical School
- University of Miami
- University of Minnesota
- University of Nebraska
- University of Pennsylvania
- University of Pennsylvania School of Veterinary Medicine
- University of Pittsburgh
- Usher Syndrome Coalition
- ValenzaBio
- Verana Health
- Versea Ophthalmics
- Vial
- Viatris
- Viela Bio
- ViGeneron
- Viralgen
- Viridian Therapeutics
- Vision Care Group
- Vision Essence
- Vision Institute
- VisionWeb
- Visiox Pharma
- Visus Therapeutics
- Vivani Medical
- VivaVision Biotech
- Vivior
- Vizient
- Vyluma
- Wagner Macula Retina Center
- Wakamoto Pharmaceutical
- Wake Forest University
- Wallace H. Coulter Foundation
- WuXi Advanced Therapies
- Xbrane Biopharma
- Xencor
- Xequel Bio
- XERIS Pharmaceuticals
- Yangtze River Pharmaceutical Group
- Yarrow Bioscience
- Ypsomed
- Zhaoke (Hong Kong) Ophthalmology Pharmaceutical
- Zhonglan Electronic Technology
- ZipBio
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
